Question 1

What is Catalyst Pharmaceuticals?

Accepted Answer

Catalyst Pharmaceuticals is a Company.

Question 2

How often does Catalyst Pharmaceuticals appear in global news?

Accepted Answer

Tracked across 5 news events drawn from 30 articles.

Question 3

When was Catalyst Pharmaceuticals first tracked by Ergen?

Accepted Answer

First tracked on Apr 23, 2026.

Question 4

When was Catalyst Pharmaceuticals last mentioned in news?

Accepted Answer

Last active on Jul 13, 2026.

Question 5

What is Catalyst Pharmaceuticals's current news sentiment?

Accepted Answer

Aggregate sentiment score: 14 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Question 6

How prominent is Catalyst Pharmaceuticals in global news coverage?

Accepted Answer

Attention score of 4, derived from article volume and coverage intensity across 5 events.

Question 7

What is the most recent event involving Catalyst Pharmaceuticals?

Accepted Answer

AGAMREE Phase 1 Study Results (Jul 01, 2026, 6 articles).

Question 8

How did the "AGAMREE Phase 1 Study Results" event impact Catalyst Pharmaceuticals?

Accepted Answer

Catalyst Pharmaceuticals conducted the Phase 1 study of AGAMREE and holds commercialization rights in North America. Positive results support its potential to expand the drug's use beyond Duchenne muscular dystrophy, increasing its market potential.

Question 9

How did the "Solaris joins S&P SmallCap 600" event impact Catalyst Pharmaceuticals?

Accepted Answer

Catalyst Pharmaceuticals is being removed from the index due to its acquisition by Angelini Pharma, a routine event for acquired companies.

Question 10

How did the "Santhera Pharmaceuticals Appoints Orlando Oliveira CEO" event impact Catalyst Pharmaceuticals?

Accepted Answer

Santhera Pharmaceuticals has partnered with Catalyst Pharmaceuticals for the North American rights to AGAMREE.

Question 11

How did the "Santhera Proposes Srishti Gupta Director" event impact Catalyst Pharmaceuticals?

Accepted Answer

Catalyst Pharmaceuticals holds the North American rights to AGAMREE, licensed from Santhera Pharmaceuticals.

Question 12

How did the "Santhera expands Biomedica distribution deal" event impact Catalyst Pharmaceuticals?

Accepted Answer

Catalyst Pharmaceuticals holds North American rights to AGAMREE; the expanded distribution does not affect its territory.

Question 13

How is this data collected?

Accepted Answer

Ergen aggregates thousands of global news sources and extracts structured events, entities, and relationships with sentiment and attention metrics. Pages are daily static snapshots from the platform's live database.